Company news
Surrozen, Inc. news in 2022
Surrozen, Inc.'s news releases, calls and decks from 2022, newest first.
Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 13, 2022
Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases
October 5, 2022
Surrozen Reports Second Quarter 2022 Financial Results
August 10, 2022
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis
June 12, 2022
Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)
May 23, 2022
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis
May 17, 2022
Surrozen Reports First Quarter 2022 Financial Results
May 10, 2022
Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 1, 2022
Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results
March 23, 2022
Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline
January 9, 2022